Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes (2011) 2.65

The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol (2011) 1.84

Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol (2012) 1.51

Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol (2012) 1.42

SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol (2013) 1.29

Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy? PLoS One (2013) 1.20

Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol (2013) 1.09

Early diabetic nephropathy in type 1 diabetes: new insights. Curr Opin Endocrinol Diabetes Obes (2014) 0.98

Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS One (2014) 0.94

Molecular determinants of renal glucose reabsorption. Focus on "Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2". Am J Physiol Cell Physiol (2010) 0.90

Aquaporin 11 insufficiency modulates kidney susceptibility to oxidative stress. Am J Physiol Renal Physiol (2013) 0.87

Antifibrotic treatment and other new strategies for improving renal outcomes. Contrib Nephrol (2011) 0.86

Sodium-retaining effect of insulin in diabetes. Am J Physiol Regul Integr Comp Physiol (2012) 0.85

SGLT2 inhibitors act from the extracellular surface of the cell membrane. Physiol Rep (2014) 0.85

A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.82

Patient considerations in the management of type 2 diabetes - critical appraisal of dapagliflozin. Patient Prefer Adherence (2014) 0.80

The prelude on novel receptor and ligand targets involved in the treatment of diabetes mellitus. Adv Pharm Bull (2014) 0.78

Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opin Ther Targets (2016) 0.77

Proximal tubule cell hypothesis for cardiorenal syndrome in diabetes. Int J Nephrol (2010) 0.77

Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab (2008) 6.22

Mouse models of diabetic nephropathy. J Am Soc Nephrol (2004) 3.95

Mouse models of diabetic nephropathy. J Am Soc Nephrol (2009) 3.74

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int (2009) 3.19

A simplified method for HPLC determination of creatinine in mouse serum. Am J Physiol Renal Physiol (2004) 2.17

The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int (2005) 2.02

Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int (2004) 2.00

AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest (2013) 1.84

A1C and survival in maintenance hemodialysis patients. Diabetes Care (2007) 1.75

Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol (2010) 1.75

Selective role for superoxide in InsP3 receptor-mediated mitochondrial dysfunction and endothelial apoptosis. J Cell Biol (2005) 1.73

Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med (2005) 1.71

Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent. Invest Radiol (2011) 1.64

Induction of AMPK activity corrects early pathophysiological alterations in the subtotal nephrectomy model of chronic kidney disease. Am J Physiol Renal Physiol (2013) 1.63

Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes (2004) 1.58

Reactive oxygen species production via NADPH oxidase mediates TGF-beta-induced cytoskeletal alterations in endothelial cells. Am J Physiol Renal Physiol (2005) 1.58

Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol (2012) 1.51

AMPK mediates the initiation of kidney disease induced by a high-fat diet. J Am Soc Nephrol (2011) 1.48

Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol (2009) 1.29

New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol (2010) 1.29

Assessment of 115 candidate genes for diabetic nephropathy by transmission/disequilibrium test. Diabetes (2005) 1.25

Role of Nox2 in diabetic kidney disease. Am J Physiol Renal Physiol (2013) 1.24

Role of Smad4 on TGF-beta-induced extracellular matrix stimulation in mesangial cells. Kidney Int (2003) 1.24

Overview: combating diabetic nephropathy. J Am Soc Nephrol (2003) 1.22

Decorin deficiency enhances progressive nephropathy in diabetic mice. Am J Pathol (2007) 1.22

Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev Mol Med (2009) 1.21

Role of upstream stimulatory factors in regulation of renal transforming growth factor-beta1. Diabetes (2005) 1.21

Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. Semin Nephrol (2007) 1.20

The endoplasmic reticulum stress response and diabetic kidney disease. Am J Physiol Renal Physiol (2011) 1.16

Obesity related kidney disease. Curr Diabetes Rev (2011) 1.14

Mechanisms of kidney fibrosis and the role of antifibrotic therapies. Curr Opin Nephrol Hypertens (2009) 1.09

TRB3 is stimulated in diabetic kidneys, regulated by the ER stress marker CHOP, and is a suppressor of podocyte MCP-1. Am J Physiol Renal Physiol (2010) 1.08

Nitrative inactivation of thioredoxin-1 and its role in postischemic myocardial apoptosis. Circulation (2006) 1.07

Novel interactions between TGF-{beta}1 actions and the 12/15-lipoxygenase pathway in mesangial cells. J Am Soc Nephrol (2004) 1.06

Glycemic control in diabetic CKD patients: where do we stand? Am J Kidney Dis (2008) 1.05

The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiol Clin (2010) 1.04

A role for the organic anion transporter OAT3 in renal creatinine secretion in mice. Am J Physiol Renal Physiol (2012) 1.02

Hyperglycemia is a major determinant of albumin permeability in diabetic microcirculation: the role of mu-calpain. Diabetes (2007) 1.02

Diabetic nephropathy: of mice and men. Adv Chronic Kidney Dis (2005) 1.02

TGF-beta-induced Ca(2+) influx involves the type III IP(3) receptor and regulates actin cytoskeleton. Am J Physiol Renal Physiol (2002) 1.01

Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes. PLoS One (2011) 1.00

Burnt-out diabetes: impact of chronic kidney disease progression on the natural course of diabetes mellitus. J Ren Nutr (2009) 0.99

Transition of kidney tubule cells to a senescent phenotype in early experimental diabetes. Am J Physiol Cell Physiol (2010) 0.97

Loss of heparan N-sulfotransferase in diabetic liver: role of angiotensin II. Diabetes (2005) 0.94

Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. Nephrol Dial Transplant (2010) 0.94

Klotho suppresses renal tubulo-interstitial fibrosis by controlling basic fibroblast growth factor-2 signalling. J Pathol (2014) 0.93

Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy. Curr Diab Rep (2004) 0.93

Isoform- and species-specific control of inositol 1,4,5-trisphosphate (IP3) receptors by reactive oxygen species. J Biol Chem (2014) 0.93

Stimulation of urinary TGF-beta and isoprostanes in response to hyperglycemia in humans. Clin J Am Soc Nephrol (2005) 0.93

Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis (2002) 0.92

Uncoupling of ER-mitochondrial calcium communication by transforming growth factor-beta. Am J Physiol Renal Physiol (2008) 0.90

Profiling of human mesangial cell subproteomes reveals a role for calmodulin in glucose uptake. Am J Physiol Renal Physiol (2007) 0.89

Beneficial Effects of AMP-Activated Protein Kinase Agonists in Kidney Ischemia-Reperfusion: Autophagy and Cellular Stress Markers. Nephron Exp Nephrol (2014) 0.89

Visualizing the mouse podocyte with multiphoton microscopy. Biochem Biophys Res Commun (2012) 0.88

Mannan-binding lectin in diabetic kidney disease: the impact of mouse genetics in a type 1 diabetes model. Exp Diabetes Res (2012) 0.88

Role of reactive oxygen species in hyperadrenergic hypertension: biochemical, physiological, and pharmacological evidence from targeted ablation of the chromogranin a (Chga) gene. Circ Cardiovasc Genet (2010) 0.88

Role of the USF1 transcription factor in diabetic kidney disease. Am J Physiol Renal Physiol (2011) 0.87

Targeted renal therapies through microbubbles and ultrasound. Adv Drug Deliv Rev (2010) 0.87

A sensitized screen of N-ethyl-N-nitrosourea-mutagenized mice identifies dominant mutants predisposed to diabetic nephropathy. J Am Soc Nephrol (2006) 0.87

Antifibrotic treatment and other new strategies for improving renal outcomes. Contrib Nephrol (2011) 0.86

Genomic strategies for diabetic nephropathy. J Am Soc Nephrol (2003) 0.84

Effects of water restriction on gene expression in mouse renal medulla: identification of 3betaHSD4 as a collecting duct protein. Am J Physiol Renal Physiol (2006) 0.83

Renal dysfunction in heart failure patients: what is the evidence? Heart Fail Rev (2007) 0.83

In vivo validation and 3D visualization of broadband ultrasound molecular imaging. Am J Nucl Med Mol Imaging (2013) 0.82

Obesity and kidney disease: differential effects of obesity on adipose tissue and kidney inflammation and fibrosis. Curr Opin Nephrol Hypertens (2015) 0.81

Autophagy and metabolic changes in obesity-related chronic kidney disease. Nephrol Dial Transplant (2013) 0.81

Renal handling of adipokines. Contrib Nephrol (2006) 0.80

Novel aspects of transforming growth factor-Beta in diabetic kidney disease. Nephron (2002) 0.80

The pathogenesis of fibrosis and renal disease in scleroderma: recent insights from glomerulosclerosis. Curr Rheumatol Rep (2004) 0.80

Sugar, sex, and TGF-β in diabetic nephropathy. Semin Nephrol (2012) 0.80

Obesity, immunomodulation and chronic kidney disease. Curr Opin Pharmacol (2013) 0.77

TGF-beta inhibits Ang II-induced MAPK p44/42 signaling in vascular smooth muscle cells by Ang II type 1 receptor downregulation. J Vasc Res (2009) 0.77

Adipokines protecting CKD. Nephrol Dial Transplant (2013) 0.77

Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer. Am J Nephrol (2016) 0.77

Effects of high-fat diet and losartan on renal cortical blood flow using contrast ultrasound imaging. Am J Physiol Renal Physiol (2013) 0.76

Regulation of transforming growth factor-beta1 by insulin in prediabetic African Americans. Kidney Int (2010) 0.75